XENCOR AND CHUGAI STRIKE CANCER ANTIBODIES DEAL

Private biopharmaceutical firm Xencor and Chugai Pharmaceutical, the fifth largest pharmaceutical company in Japan in terms of sales, have formed a license and collaboration agreement to create monoclonal antibodies to be used against a proprietary cancer target. Chugai will use Xencor's XmAb technology on its antibodies against a cancer target.

Pharmaceutical Business Review Online (http://www.pharmaceutical-business-review.com/article_news.asp?guid=8672704B-808E-48D4-B577-60DAFD36CEBC)